featured
2024 Top Story in Oncology: Triplet Therapy for HR+/HER2− Metastatic Breast Cancer
Written by
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Jhaveri KL, Accordino MK, Bedard PL, et al. Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer. J Clin Oncol. 2024;42(33):3947–3956.
- Turner NC, Im SA, Saura C, et al. Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer. N Engl J Med. 2024;391(17):1584–1596.
- Cristofanilli M, Rugo HS, Im SA, et al. Overall Survival With Palbociclib and Fulvestrant in Women With HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-Blind, Phase III Randomized Study. Clin Cancer Res. 2022;28(16):3433–3442.
Disclosure statements are available on the authors' profiles: